Kvartalsrapport Q3 2026. Stark lönsamhet och positiv utveckling i Nordamerika (MAR)

Q3 net sales fell to SEK 26.225 million from SEK 29.887 million, while EBITDA rose to SEK 4.146 million from SEK 3.861 million and profit before tax increased to SEK 2.968 million from SEK 1.991 million. Earnings per share improved to SEK 0.16 from SEK 0.11; the company cited continued strong profitability and positive development in North America. For the first nine months of 2026, sales and EBITDA were lower year over year, at SEK 88.953 million and SEK 7.890 million, respectively.

Analysis

The key signal is improved quarterly profit conversion despite weaker sales: quarterly EBITDA margin works out to roughly 15.8%, versus 12.9% a year earlier. That points to better cost control, mix, or lower operating expense—but the release does not identify which, so investors should not underwrite it as structural yet. The year-to-date margin is still below the prior-year period, making the quarter a possible inflection rather than confirmation. The claimed North American momentum could become a meaningful offset to softer consolidated revenue, but without segment sales, growth rates, or order data it is not independently assessable. The November 25 extraordinary meeting is a near-term governance catalyst; its agenda and any financing, capital-allocation, or ownership implications need verification. For the next 1–3 months, the deciding evidence is whether revenue stabilizes while EBITDA conversion holds. Over 6–18 months, sustained North American growth could improve the earnings mix; continued revenue erosion would instead expose the latest profitability to reversal. The contrarian risk is that investors capitalize one strong-margin quarter while the underlying demand trend remains weak. No issuer identity or ticker is supplied, so there is no grounded single-name trade recommendation.

Key Decisions for Investors

• Treat the quarter as an earnings-quality watch, not yet a trend change. Before adding exposure, verify the next report’s segment-level North American revenue, organic growth, and explanation of cost or mix gains.
• Avoid extrapolating the quarterly margin improvement into forward earnings until it repeats. A renewed decline in sales accompanied by EBITDA margin falling back toward the year-to-date level would falsify the operating-improvement thesis.
• Check the November 25 meeting notice and resolutions for financing, dilution, asset transactions, or governance changes; keep the event on the catalyst calendar until the agenda is clear.
• No actionable pair or options trade is supported by the supplied information. Reassess once the issuer/ticker, share liquidity, valuation, and segment disclosures are available.